UM LAPs- U10 Grant

描述（由申请人提供）：密歇根大学（UM），包括其综合癌症中心（UMCCC）和医学院部门，申请其作为NCI国家临床试验网络主要学术参与站点（NCTN lap - u10）的首届UI0奖。我们认为这个机会是我们机构大型癌症研究工作的重要组成部分。我们仍然致力于多机构合作对癌症治疗进步至关重要的概念。作为LAP站点，我们的目标是为NCTN研究和改进癌症治疗的努力做出重大的科学、管理和患者数据贡献。NCTN过程包括收集患者数据，采用统一的毒性和反应标准，以及进行有目的的临床试验。合作小组研究是唯一的设置，其中复杂的概念，联合模式和跨学科治疗以及辅助治疗可以适当地评估。合作小组还提高了对预后因素、治疗和患者结果之间重要关系的理解，这是其他方法无法获得的。

DESCRIPTION (provided by applicant): The University of Michigan (UM), inclusive of its Comprehensive Cancer Center (UMCCC) and Medical School Departments, requests its inaugural UI0 award as an NCI National Clinical Trials Network Lead Academic Participating Site (NCTN LAPS-U10). We view this opportunity as an important component of a large cancer research effort at our institution. We remain committed to the concept that multi-institutional collaboration is essential to the advancement of cancer treatment. Our goal as a LAP Site is to make significant scientific, administrative and patient data contributions to the NCTN effort to study and improve cancer therapy. The NCTN process involves the collection of patient data, adoption of uniform toxicity and response criteria, and conduction of purposeful clinical trials. Cooperative group research is the only setting in which sophisticated concepts of combined modality and interdisciplinary therapy as well as adjuvant therapies can be properly evaluated. The cooperative groups have also provided improved understanding of the important relationships between prognostic factors, therapy and patient outcomes that could not have been obtained otherwise.